For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System

InspireMD is Also Proud to Announce That MGuard(TM) is Now Available With an Improved Delivery System

PARIS, May 26, 2010 - InspireMD, Ltd. announced today the next generation MGuard stent,
MGuard Prime(R), a net protective Cobalt Chromium stent system. MGuard
Prime(R) offers an advanced patented Cobalt Chromium design, superior
flexibility and excellent deliverability on top of the established benefits
of the MGuard MicroNet(R) technology.

MGuard(TM) is now available with an improved delivery system.
Recently InspireMD introduced MGuard with a new improved delivery system in
selected regions. The new delivery system offers a state of the art design
and a superior deliverability. "We are very pleased with the flexibility and
performance of the new delivery system. In our testing we have experienced a
15% improvement in crossing profile and 45% improvement in pushability
resistance. These improvements will directly benefit Acute MI patients
throughout the world," said Eli Bar, CTO and VP R&D of InspireMD.

InspireMD will hold an Evening Symposium at the PCR this evening
at 6:30-8:00pm at the Concorde Lafayette Hotel in Paris. The symposium
"MGuard - 2 Years Experience in Acute MI" will be chaired by Dr. Martin B.
Leon.

MGuard final adjudicated results of the MAGICAL trial, including
the long awaited 6 months clinical FU results, will be presented for the
first time at the EuroPCR. The MAGICAL Trial is a 60 patients STEMI study.
Acute results as well as interim 30 day clinical results have previously
been presented by Dr. Dariusz Dukek, the study's primary investigator.

Also coming up at the EuroPCR, presented for the first time, the
final adjudicated results of the INSPIRE trial, and long awaited 1 year
clinical FU with 6 month angiographic results.

The INSPIRE Trial from Sao-Paulo, Brazil is a 30 patients' study
that enrolled SVG and native coronary patients. Acute results as well as
interim results have previously been presented by Dr. A. Abizaid, the study's
primary investigator.

The international iMOS registry has crossed the 200 patients' milestone.
The registry will enroll 1000 'real world' MGuard(TM) patients in
Europe, Asia and South America. Data from the registry, an unselected
heterogeneous population, will be used to support data from other clinical
studies. Interim data analysis will be presented by Prof. GB. Danzi, from the
iMOS steering committee, at InspireMD's evening symposium this evening.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with
an embolic protection. The embolic protection is comprised of an ultra-thin
polymer mesh sleeve that wraps the stent. The protective sleeve is composed
of a micron-level-fiber which is knit in order to ensure flexibility while
retaining the strength characteristics of the fiber material. The sleeve is
designed to expand seamlessly when the stent is deployed, without affecting
the structural integrity of the stent. The MGuard(TM) coronary stent provides
permanent embolic protection, without complicating deliverability. Reduced
injury to the vessel as a result of diffused stent pressure is a benefit of
the sleeve which may lead to lower risk of restenosis. MGuard(TM) is CE Mark
approved.

The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic
welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD Ltd. is an innovative medical device company focusing on the
development and commercialization of its proprietary stent system technology,
MGuard(TM). The company intends to apply its technology to develop products
used in interventional cardiology and other vascular procedures. InspireMD's
mission is to utilize its proprietary technology to make its products the
industry standard for stents and to provide a superior solution to the key
clinical issues of current stenting: restenosis, embolic showers, and late
thrombosis. In addition to providing embolic protection and minimizing
arterial injury, this promising technology can be an effective and uniform
drug delivery mechanism with the help of the novel micron-level net for next
generation drug eluting stents. InspireMD intends to pursue applications of
this technology both for bare metal and drug eluting stents in coronary,
carotid and peripheral artery procedures.

For further information visit www.inspire-md.com

    Contact:

    Jonina Ohayon
    Marketing Director
    Tel +972-52-5791120
    jonina@inspire-md.com

Contact: Jonina Ohayon, Marketing Director, Tel +972-52-5791120, jonina at inspire-md.com